Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-09-22-Speech-3-963"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2010-09-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"de"^^xsd:language2
lpv:document identification number	"en.20100922.20.3-963"2
lpv:hasSubsequent	lp_eu:2010-09-22-Speech-3-2072
lpv:speaker	lp:Franz Obermayr2
lpv:spokenAs	substitute; EMPL (2009-07-16--2012-01-18)3 substitute; Delegation to the EU-Kazakhstan, EU-Kyrgyzstan and EU-Uzbekistan Parliamentary Cooperation Committees, and for relations with Tajikistan, Turkmenistan and Mongolia (2009-09-16--2014-06-30)3 unknown; Freiheitliche Partei Österreichs (2009-07-14--2014-06-30)3 member; Delegation for relations with Iran (2009-09-16--2012-02-12)3 member; REGI (2009-07-16--2012-01-18)3 member; NA (2009-07-14--2014-06-30)3
lpv:translated text	"Pharmacovigilance is used to monitor the safety of medicinal products after they have been authorised and therefore plays an important role in public health. Side effects from drugs that are rare, only appear after long-term use, or only in interaction with other drugs, can be missed in clinical trials. Thus, an estimated 197 000 deaths per year are caused by Adverse Drug Reactions (ADRs) in the EU. A system for reporting adverse reactions and looking for patterns in these reactions are therefore important elements of an efficient health policy. By strengthening cooperation on pharmacovigilance at EU level, the ‘pool’ of reported ADRs is larger, meaning rarer patterns can be picked up more quickly, duplicate work on following up the same ADRs in different Member States can be avoided and unsafe medicines can be withdrawn quickly when required. I therefore voted in favour of this report."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph